Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081042 · ClinicalTrials.gov registry record · Phase 2
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00081042: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00081042 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081042, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.
Interventions
- DRUG paclitaxel albumin-stabilized nanoparticle formulation
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00081042 record still lists
NCT00081042 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which paclitaxel albumin-stabilized nanoparticle formulation is the first listed.
NCT00081042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00081042 about?
NCT00081042 is a clinical study titled "ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma". RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.
What is the current status of trial NCT00081042?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00081042?
The interventions under investigation include: paclitaxel albumin-stabilized nanoparticle formulation (DRUG).
Who is sponsoring clinical trial NCT00081042?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia